Company description
Development of therapeutic agents for severe acute respiratory syndrome (SARS) viral infection using short interfering RNA (siRNA) inhibitors exemplifies a powerful new means to combat the recently emerging SARS-CoV-2. Integrated processes within Creative Biolabs’ siRNA drug development platform provide a total solution for siRNA therapeutics discovery and development, from siRNA design, synthesis to preclinical tests. With our advanced siRNA core technologies and manufacturing infrastructure, Creative Biolabs is the ideal partner for different industries currently working on the development of siRNA therapeutics for SARS-CoV-2.
